Amplification and Selection of Antimicrobial Resistance in the Intestine II (ASARI II)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03140826|
Recruitment Status : Recruiting
First Posted : May 4, 2017
Last Update Posted : May 3, 2018
|Condition or disease||Intervention/treatment|
|Antibiotic Selection Pressure||Drug: meropenem|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Amplification and Selection of Antimicrobial Resistance in the Intestine II|
|Actual Study Start Date :||January 30, 2018|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||July 2020|
Patients receiving meropenem to treat an infection.
Antibiotics to treat infections.
Other Name: piperacillin-tazobactam
Patients receiving piperacillin-meropenem to treat an infection.
- Antibiotic Selection Pressure [ Time Frame: under treatment, max. 10 days ]Degree of the change of the intestinal resistome.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03140826
|Contact: Matthias Willmann, Prof. Dr.||+49 firstname.lastname@example.org|
|University Hospital Cologne||Recruiting|
|Cologne, Germany, 50935|
|Contact: Maria Vehreschild, Dr|
|Institute of Medical Microbiology and Hygiene, University Hospital of Tuebingen||Recruiting|
|Tuebingen, Germany, 72076|
|Contact: Matthias Willmann, MD +49 7071 29-81527 email@example.com|
|Principal Investigator:||Matthias Willmann, Prof. Dr.||University Tuebingen|